Literature DB >> 15302200

Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation.

Mervyn Singer1, Vincenzo De Santis, Domenico Vitale, William Jeffcoate.   

Abstract

Sepsis and other critical illnesses produce a biphasic inflammatory, immune, hormonal, and metabolic response. The acute phase is marked by an abrupt rise in the secretion of so-called stress hormones with an associated increase in mitochondrial and metabolic activity. The combination of severe inflammation and secondary changes in endocrine profile diminish energy production, metabolic rate, and normal cellular processes, leading to multiple organ dysfunction. This perceived failure of organs might instead be a potentially protective mechanism, because reduced cellular metabolism could increase the chances of survival of cells, and thus organs, in the face of an overwhelming insult. We propose that, first, multiple organ failure induced by critical illness is primarily a functional, rather than structural, abnormality. Indeed, it may not be failure as such, but a potentially protective, reactive mechanism. Second, the decline in organ function is triggered by a decrease in mitochondrial activity and oxidative phosphorylation, leading to reduced cellular metabolism. Third, this effect on mitochondria might be the consequence of acute-phase changes in hormones and inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302200     DOI: 10.1016/S0140-6736(04)16815-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  137 in total

1.  Think locally: evaluation of the microcirculation in sepsis.

Authors:  Steve M Hollenberg
Journal:  Intensive Care Med       Date:  2010-08-20       Impact factor: 17.440

Review 2.  Hypothesis: Fever control, a niche for alpha-2 agonists in the setting of septic shock and severe acute respiratory distress syndrome?

Authors:  F Petitjeans; S Leroy; C Pichot; A Geloen; M Ghignone; L Quintin
Journal:  Temperature (Austin)       Date:  2018-05-22

Review 3.  Normalizing physiological variables in acute illness: five reasons for caution.

Authors:  Brian P Kavanagh; L Joanne Meyer
Journal:  Intensive Care Med       Date:  2005-07-26       Impact factor: 17.440

4.  Acute kidney injury in sepsis: is renal blood flow more than just an innocent bystander?

Authors:  Martin Matejovic; Peter Radermacher; Michael Joannidis
Journal:  Intensive Care Med       Date:  2007-09       Impact factor: 17.440

5.  NETWORKS, BIOLOGY AND SYSTEMS ENGINEERING: A CASE STUDY IN INFLAMMATION.

Authors:  P T Foteinou; E Yang; I P Androulakis
Journal:  Comput Chem Eng       Date:  2009-12-10       Impact factor: 3.845

Review 6.  A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury.

Authors:  Hernando Gomez; Can Ince; Daniel De Backer; Peter Pickkers; Didier Payen; John Hotchkiss; John A Kellum
Journal:  Shock       Date:  2014-01       Impact factor: 3.454

Review 7.  Peritoneal damage: the inflammatory response and clinical implications of the neuro-immuno-humoral axis.

Authors:  Tarik Sammour; Arman Kahokehr; Mattias Soop; Andrew G Hill
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 8.  Sepsis-induced acute kidney injury.

Authors:  Hernando Gómez; John A Kellum
Journal:  Curr Opin Crit Care       Date:  2016-12       Impact factor: 3.687

9.  Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2013-09-10       Impact factor: 3.584

10.  Enteral nutrition is associated with improved outcome in patients with severe sepsis. A secondary analysis of the VISEP trial.

Authors:  G Elke; E Kuhnt; M Ragaller; D Schädler; I Frerichs; F M Brunkhorst; M Löffler; K Reinhart; N Weiler
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-03-03       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.